Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Films like Strong: Living with Multiple Myeloma are essential. Multiple Myeloma is not exactly high on the list of diseases ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

The main focus right now in the myeloma paradigm of treatment is, okay, how do we harness the best power of CAR-T? We're doing it later in the treatment of myeloma. We've tried to move it earlier, and ...

The clinicogenomic features of these CAR transgenic T-cell lymphoproliferative neoplasms suggest that multiple potential ... melphalan with autologous stem-cell transplantation and then ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone or Rvd Plus ...